Delivery Order SPE2DB22D2211-SPE2DB26FRGVR
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,119.69 for SKYRIZI 600 mg/10 mL vials on July 14, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order is not set-aside and represents a competitive award. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office operations. This delivery order is issued...
- The Defense Logistics Agency awarded a $27,497.28 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen/mL pharmaceutical supplies on August 6, 2025. This non-set-aside, firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $26,546.03 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen, a pharmaceutical product. This firm fixed-price contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a non-competitive delivery order issued without set-aside designation. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $42,191.28 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen medication on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed price contract represents a non-competitive set-aside delivery against AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $89,511.22 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen/mL pharmaceutical products on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed price contract is non-set-aside and utilizes AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at approximately $55,954.56 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML in pen/milliliter format. This is a firm fixed price, non-set-aside contract with a completion date of September 30, 2025, issued on September 29, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $17,574.35 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen vials under a firm fixed price contract type. This competitive award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery location is specified as Conshohocken, Pennsylvania, the company's corporate...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $17,097.24 by the Defense Logistics Agency on August 20, 2025, for the supply of SKYRIZI 150 MG/ML per milliliter. This is a firm fixed price contract with no set-aside designation, reflecting a competitively awarded transaction. The contract is scheduled for ultimate completion by August 21, 2025, with performance taking place at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $32,133.89 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML, a prescription pharmaceutical product. This competitive delivery order, issued on July 15, 2025, with a completion date of July 16, 2025, represents a firm fixed-price transaction with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $12,604.63 for SKYRIZI 360 mg/2.4 ml on-body injectable pharmaceutical product. This competitively awarded, firm fixed-price delivery order was issued on April 24, 2025, with an ultimate completion date of May 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB26FRGVRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $36,718.14 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 600 mg/10 mL vials. This competitively awarded, firm fixed-price delivery order was executed on October 17, 2025, with an ultimate completion date of November 7, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026, which enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems worldwide. As a major pharmaceutical distributor headquartered in Pennsylvania, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency and other military healthcare customers. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical requirements, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. No set-aside designation was applied to this delivery order, reflecting AmerisourceBergen's demonstrated capability to compete successfully in open federal procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.7k | 10/17/25 |